Mode
Text Size
Log in / Sign up
Phase 2 N=364 Randomized Triple-blind Treatment

Discontinuing NSAIDs in Veterans With Knee Osteoarthritis

Knee Osteoarthritis

Enrolled (actual)
364
Serious AEs
1.9%
Results posted
Dec 2019
Primary outcome: Primary: Primary Endpoint: WOMAC Pain Score (Likert Scale Version) at 4 Weeks — 8.08; 6.73 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Meloxicam 15 mg po QD (Drug); Cognitive Behavioral Therapy (Behavioral)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Oct 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Primary Endpoint: WOMAC Pain Score (Likert Scale Version) at 4 Weeks
8.08; 6.73
SECONDARY
Area Under the Curve (AUC) of the WOMAC Pain Scale Score Over 14 Weeks
7.48; 6.43
SECONDARY
Lower Extremity Disability
18.8; 19.7
SECONDARY
Global Impression of Change
2.15; 2.30
SECONDARY
Adherence to Study Medication (Assessed in Weeks Adherent)
4; 13
SECONDARY
Adherence to Study Medication (Assessed in % of Weeks With Perfect Adherence)
87; 91

Summary

Knee osteoarthritis (OA) is now recognized as a major health problem. It is the number one cause of lower extremity disability and has significant deleterious effects on quality of life. While there are numerous therapies available for knee OA, most have limited efficacy. Of particular concern, is the widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) for this disorder. Veterans, as a group, are at high risk for both gastrointestinal and cardiovascular NSAID-induced complications. In this study the investigators propose to examine whether replacing NSAIDs with cognitive behavioral therapy delivered by telephone is an effective strategy for Veterans with knee OA. Telephone-administered therapy is particularly appealing since Veterans with knee OA are more likely to have limited mobility. If successful, this program may result in significant cost-savings for both Veterans (decreased co-pays and transportation costs) and the VA (decreased hospitalizations due to NSAID induced toxicity).

Eligibility Criteria

Inclusion Criteria

Subjects will include those for whom a discontinuation trial of NSAIDs is most appropriate: 1) Veterans with knee pain despite NSAID use and/or 2) Veterans at relatively higher risk of NSAID toxicity 55-59 as ascertained by meeting 1 or more of the following 4 criteria:

  • Answer affirmatively to the question: "Do you have some knee pain on most days over the past 3 months?"
  • Have 1 or more risk factors for NSAID-induced nephrotoxicity (age greater than 60 years, atherosclerotic cardiovascular disease, current diuretic use, chronic renal insufficiency, congestive heart failure (New York Heart Association class I-II. Note, Class III and IV are excluded).
  • Have 1 or more risk factors for NSAID-induced gastrointestinal toxicity (history of peptic ulcer disease, age > 65 years, concurrent use of daily ASA or corticosteroids), and are currently on a gastro-protective agent.
  • Have 1 or more risk factors for NSAID-induced cardiovascular toxicity (prevalent cardiovascular disease, hypertension, hypercholesterolemia, diabetes, smoking, family history of early heart disease or age greater than 55 years for women).

In addition, subjects must:

  • Be age 20 years or older. While the usual cut off for knee OA is approximately 40 years, the investigators chose to lower the age cutoff as younger Veterans have a higher than expected risk of OA (see B.1).
  • Have radiographic evidence of knee OA reported in the VistA electronic system.
  • Be using an NSAID (other than daily ASA) for knee pain on most days of the month for at least the past 3 months.
  • Be able to understand and speak English and have a telephone.
  • Be willing to engage in a CBT program, to discontinue (or replace) their NSAID, and to restrict co-therapies to acetaminophen for 14 weeks.

Exclusion Criteria

  • Subjects desiring escalation of analgesics for their current level of knee pain as determined by endorsement of the following statement: "Is your knee pain bad enough that you want to talk to your doctor about taking stronger pain medications?"
  • Current use of opioids and/or Celebrex.
  • Current use of an NSAID (not including ASA) for a painful condition in addition to knee OA.
  • Contraindications to chronic NSAID use: current use of warfarin or antiplatelet agent other than ASA, allergy to any NSAID, active upper gastrointestinal ulceration in the previous 30 days, upper gastrointestinal bleeding in the past year, history of gastroduodenal perforation or obstruction, cardiovascular event within the past 6 months (myocardial infarction, cerebrovascular event, coronary-artery bypass graft, invasive coronary revascularisation, or new-onset angina), severe congestive heart failure (New York Heart Association class III-IV), evidence of serious anemia, hepatic, renal (including nephrotic syndrome), or blood coagulation disorders, and pregnancy.

***Though the investigators are proposing a RWT - and thus will not be initiating NSAID therapy - it would not be appropriate to continue NSAIDs (even when prescribed) in high-risk patients. The investigators acknowledge that these exclusion criteria limit generalizability, but the investigators feel justified to ensure subjects' safety.***

  • Previous hyaluronic acid knee injections (within 6 months) or corticosteroid knee injections (within 3 months).
  • Scheduled knee hyaluronic acid or corticosteroid injections, arthroscopy, or knee surgery.
  • Co-morbid conditions that include the following: known other causes of arthritis (infectious arthritis, rheumatoid arthritis, connective tissue disease, or psoriatic arthritis), gout or pseudogout attack within the last 12 months, peripheral neuropathy or cardiopulmonary disease that limits walking more than knee pain, bone metastases or Paget's disease involving the lower extremities, and history of drug or alcohol abuse within the past 2 years, bilateral knee replacements or knee pain in the replaced knee only.
  • Current involvement in litigation or receiving workmen's c
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01799213). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search